The medical device maker has completed more than 40 acquisitions in recent years, helping turn it into one of the state’s ...

Boston Scientific expects to complete enrollment in the coming months in the study comparing pulsed field ablation to ...

Expanding its portfolio further into cardiovascular health, Marlborough medical device manufacturer Boston Scientific has ...

Boston Scientific will purchase Ajax Health's Cortex and its OptiMap system to guide physicians performing AFib-treating ...

We recently published a list of 8 Most Promising Medical Stocks According to Hedge Funds. In this article, we are going to ...

Boston Scientific's strong history, margins, and pipeline make it a buy despite other analysts' Hold rating, with 15% growth ...

Bank of America Securities analyst Travis Steed maintained a Buy rating on Boston Scientific (BSX – Research Report) today. The ...

Cortex adds to Boston Scientific’s electrophysiology portfolio amid treatment shifts in the space driven by new pulsed field ...

Boston Scientific is resuming its "Avant Guard" study of pulse field ablation (PFA) as a first-line therapy for atrial ...

Marlborough-based Boston Scientific increased its estimated net sales growth for 2024. Meanwhile, Thermo Fisher slightly raised its full-year adjusted earnings per share guidance. Boston ...

Boston Scientific temporarily paused enrolment in its AVANT GUARD trial in October to “assess a few unanticipated ...

Late last month, Boston Scientific announced it was pausing a study examining pulsed field ablation as a first-line therapy.